http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yi-Tsung Huang (검색결과 20 건)
- 무료
- 기관 내 무료
- 유료
-
-
-
Medullary sponge kidney on retrograde pyelography
Tsung-Yi Huang,Jih-Pin Lin,Shu-Pin Huang 전남대학교 의과학연구소 2014 전남의대학술지 Vol.50 No.1
A woman aged 31 had recurrent urinary tract infection with bloody urine. A series imageof medullary sponge kidney presented by intravenous urography (IVU) was detecteddynamically by retrograde pyelography (RP). Other than ultrasonography and IVU,RP is also a reliable method to detect medullary sponge kidney.
-
-
Yi-Yang Lien,Chi-Hung Huang,Fang-Chun Sun,Shyang-Chwen Sheu,Tsung-Chi Lu,Meng-Shiunn Lee,Shu-Chin Hsueh,Hsi-Jien Chen,Meng-Shiou Lee 대한수의학회 2012 JOURNAL OF VETERINARY SCIENCE Vol.13 No.1
Chicken anemia virus (CAV) is an important viral pathogen that causes anemia and severe immunodeficiency syndrome in chickens worldwide. In this study, a potential diagnostic monoclonal antibody against the CAV VP1 protein was developed which can precisely recognize the CAV antigen for diagnostic and virus recovery purposes. The VP1 gene of CAV encoding the N-terminus-deleted VP1 protein, VP1Nd129, was cloned into an Escherichia (E.) coli expression vector. After isopropyl-b-D-thiogalactopyronoside induction, VP1Nd129 protein was shown to be successfully expressed in the E. coli. By performing an enzyme-linked immunoabsorbent assay using two coating antigens, purified VP1Nd129 and CAV-infected liver tissue lysate, E3 monoclonal antibody (mAb) was found to have higher reactivity against VP1 protein than the other positive clones according to the result of limiting dilution method from 64 clones. Using immunohistochemistry, the presence of the VP1-specific mAb, E3, was confirmed using CAV- infected liver and thymus tissues as positive-infected samples. Additionally, CAV particle purification was also performed using an immunoaffinity column containing E3 mAb. The monoclonal E3 mAb developed in this study will not only be very useful for detecting CAV infection and performing histopathology studies of infected chickens, but may also be used to purify CAV particles in the future.
-
CONSUMER EMOTION ELICITATION AND POST-EXPERIENCE BEHAVIORS
Yen-Tsung Huang,Yi-Ju Su 글로벌지식마케팅경영학회 2014 Global Marketing Conference Vol.2014 No.7
How the events of service experiences stimulus consumers’ emotional elicitation and post-experience has become an important issue in marketing. Appraisal theory is the one that has been discussed from many scholars about this significant phenomenon since a long time; nevertheless, existing studies of appraisal theory have neglected expectedness and novelty appraisals on consumers, emotional elicitation and post-experience behavior in service experiences. This research aims to examine the influences of three appraisals-goal congruence, expectedness and novelty on consumers’ emotional elicitation and their satisfaction, WOM intentions and likelihood of generating WOM under service experience scenarios. This study contains two studies: study one examines main effects of goal congruence and expectedness on emotions and post-experience; study two tests the main effects of goal congruence and novelty on emotions. Experimental design is adopted in examining appraisals on emotions. Circumplex Model of Affect is adopted as the examination of emotions. The research hypotheses are tested using MANOVA as well as Regression analyses with experimental data from 320 university students in Taiwan. The research is the first in the literature on Appraisal Theory of emotional elicitation that both expectedness and novelty has main effects on emotional elicitation as well as consumer post-experience behavior. The higher expectedness one event is, the more positive emotions will be; vice versa. Also, the more novelty one event is, the more positive emotions will be; vice versa. Positive emotions have positive impact on consumer post-experience behavior; vice versa. Main effect of goal congruence on emotions shows significant in study one whereas in study two it shows no significant influence. The research is one of the few which investigate expectedness and novelty appraisals in appraisal theory that will cause emotional elicitation as well as consumer post-experience behavior.
-
CONSUMER EMOTION ELICITATION AND POST-EXPERIENCE BEHAVIORS
Yen-Tsung Huang,Yi-Ju Su 글로벌지식마케팅경영학회 2014 Global Marketing Conference Vol.2014 No.10
How the events of service experiences stimulus consumers’ emotional elicitation and post-experience has become an important issue in marketing. Appraisal theory is the one that has been discussed from many scholars about this significant phenomenon since a long time; nevertheless, existing studies of appraisal theory have neglected expectedness and novelty appraisals on consumers, emotional elicitation and post-experience behavior in service experiences. This research aims to examine the influences of three appraisals-goal congruence, expectedness and novelty on consumers’ emotional elicitation and their satisfaction, WOM intentions and likelihood of generating WOM under service experience scenarios. This study contains two studies: study one examines main effects of goal congruence and expectedness on emotions and post-experience; study two tests the main effects of goal congruence and novelty on emotions. Experimental design is adopted in examining appraisals on emotions. Circumplex Model of Affect is adopted as the examination of emotions. The research hypotheses are tested using MANOVA as well as Regression analyses with experimental data from 320 university students in Taiwan. The research is the first in the literature on Appraisal Theory of emotional elicitation that both expectedness and novelty has main effects on emotional elicitation as well as consumer post-experience behavior. The higher expectedness one event is, the more positive emotions will be; vice versa. Also, the more novelty one event is, the more positive emotions will be; vice versa. Positive emotions have positive impact on consumer post-experience behavior; vice versa. Main effect of goal congruence on emotions shows significant in study one whereas in study two it shows no significant influence. The research is one of the few which investigate expectedness and novelty appraisals in appraisal theory that will cause emotional elicitation as well as consumer post-experience behavior.
-
Yen-Hsiang Huang,Kuo-Hsuan Hsu,Chun-Shih Chin,Jeng-Sen Tseng,Tsung-Ying Yang,Kun-Chieh Chen,Kang-Yi Su,Sung-Liang Yu,Jeremy J.W. Chen,Gee-Chen Chang 대한암학회 2022 Cancer Research and Treatment Vol.54 No.2
Purpose The aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. Materials and Methods From August 2016 to October 2020, we enrolled advanced lung adenocarcinoma patients harboring exon 19 deletion or L858R receiving gefitinib, erlotinib and afatinib plus bevacizumab as the first-line treatment for the purposes of analysis. Results A total of 36 patients were included in the final analysis. Three patients received gefitinib, 17 received erlotinib, and 16 received afatinib combined with bevacizumab as the first-line treatment. The objective response rate was 77.8%, and disease control rate was 94.4%. The overall median progression-free survival (PFS) was 16.4 months, while the median PFS was 17.1 months in patients with exon 19 deletion, and 16.2 months in patients with L858R mutation (p=0.311). Regarding the use of different EGFR-TKIs, the median PFS was 17.1 months in the erlotinib group and 21.6 months in the afatinib group (p=0.617). In patients with brain metastasis at baseline, the median PFS was 18.9 months in the erlotinib group and 16.4 months in the afatinib group (p=0.747). Amongst patients harboring exon 19 deletion, the median PFS was 16.2 months in the erlotinib group and not-reached in the afatinib group (p=0.141). In patients with L858R mutation, the median PFS was 18.9 months in the erlotinib group and 16.2 months in the afatinib group (p=0.481). Conclusion Our research demonstrates that not only erlotinib combined with bevacizumab, but also afatinib plus bevacizumab as first-line treatment, provides solid clinical efficacy in advanced EGFR-mutant lung adenocarcinoma patients. PurposeThe aim of this study was to investigate the efficacy of various epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) plus bevacizumab in advanced <i>EGFR</i>-mutant lung adenocarcinoma patients.Materials and MethodsFrom August 2016 to October 2020, we enrolled advanced lung adenocarcinoma patients harboring exon 19 deletion or L858R receiving gefitinib, erlotinib and afatinib plus bevacizumab as the first-line treatment for the purposes of analysis.ResultsA total of 36 patients were included in the final analysis. Three patients received gefitinib, 17 received erlotinib, and 16 received afatinib combined with bevacizumab as the first-line treatment. The objective response rate was 77.8%, and disease control rate was 94.4%. The overall median progression-free survival (PFS) was 16.4 months, while the median PFS was 17.1 months in patients with exon 19 deletion, and 16.2 months in patients with L858R mutation (p=0.311). Regarding the use of different EGFR-TKIs, the median PFS was 17.1 months in the erlotinib group and 21.6 months in the afatinib group (p=0.617). In patients with brain metastasis at baseline, the median PFS was 18.9 months in the erlotinib group and 16.4 months in the afatinib group (p=0.747). Amongst patients harboring exon 19 deletion, the median PFS was 16.2 months in the erlotinib group and not-reached in the afatinib group (p=0.141). In patients with L858R mutation, the median PFS was 18.9 months in the erlotinib group and 16.2 months in the afatinib group (p=0.481).ConclusionOur research demonstrates that not only erlotinib combined with bevacizumab, but also afatinib plus bevacizumab as first-line treatment, provides solid clinical efficacy in advanced <i>EGFR</i>-mutant lung adenocarcinoma patients.
-
Yen-Hsiang Huang,Kuo-Hsuan Hsu,Jeng-Sen Tseng,Kun-Chieh Chen,Chia-Hung Hsu,Kang-Yi Su,Jeremy J. W. Chen,Huei-Wen Chen,Sung-Liang Yu,Tsung-Ying Yang,Gee-Chen Chang 대한암학회 2018 Cancer Research and Treatment Vol.50 No.4
Purpose The main objective of this study was to investigate the relationship among the clinical characteristics and the frequency of T790M mutation in advanced epidermal growth factor receptor (EGFR)mutant lung adenocarcinoma patients with acquired resistance after firstline EGFRtyrosine kinase inhibitor (TKI) treatment. Materials and Methods We enrolled EGFR-mutant stage IIIB-IV lung adenocarcinoma patients, who had progressed to prior EGFR-TKI therapy, and evaluated their rebiopsy EGFRmutation status. Results A total of 205 patients were enrolled for analysis. The overall T790M mutation rate of rebiopsy was 46.3%. The T790M mutation rates among patients with exon 19 deletion mutation, exon 21 L858R point mutation, and other mutations were 55.0%, 37.3%, and 27.3%, respectively. Baseline exon 19 deletion was associated with a significantly higher frequency of T790M mutation (adjusted odds ratio, 2.14; 95% confidence interval [CI], 1.20 to 3.83; p=0.010). In the exon 19 deletion subgroup, there was a greater prevalence of T790M mutation than other exon 19 deletion subtypes in patients with the Del E746-A750 mutation (61.6% vs. 40.6%; odds ratio, 2.35; 95% CI, 1.01 to 5.49; p=0.049). The progression- free survival (PFS) of first-line TKI treatment > 11 months was also associated with a higher T790M mutation rate (54.1% vs. 39.3%; adjusted odds ratio, 1.82; 95% CI, 1.02 to 3.25; p=0.044). Patients who underwent rebiopsy at metastatic sites had more chance to harbor T790M mutation (52.6% vs. 33.8%; adjusted odds ratio, 1.97; 95% CI, 1.06 to 3.67; p=0.032). Conclusion PFS of first-line EGFR-TKI, rebiopsy site, EGFR exon 19 deletion and its subtype Del E746- A750 mutation are associated with the frequency of T790M mutation.
-
Where Are Landscape Designers' Spatial Abilities in the Brain? An fMRI Study
Shih-Han Hung,Chia-Yi Huang,Tsung-Ren Huang,Shih-An Tang,Yu-Ping Tsai,Chun-YenChang 인간식물환경학회 2023 인간식물환경학회지 Vol.26 No.5
Background and objective: To effectively understand and communicate their work, landscape designers should possessexcellent spatial abilities. Neurological methods have confirmed that activation of the occipital lobe, parietal cortex, andprefrontal cortex affect the judgment of space; however, few studies have measured spatial abilities in landscape design. This study aimed to identify the potential role of various brain regions during spatial interpretation processes by landscapedesigners, particularly the effect of stimulating the frontal lobe on enhancing design capabilities. Methods: This study tested the spatial abilities of landscape designers when transforming a planar drawing into a sectionaldrawing and the brain regions activated in this process. The subjects were asked to identify the correct option whenmatching given section lines in a planar drawing. The correct answer rate and response time were used to score brainactivation during spatial task processes. A total of 16 valid subjects were divided into high- and low-accuracy groupsaccording to the correct answer rate. Results: The results for the high-accuracy group showed that the left inferior frontal gyrus was activated during spatialdesign tasks. In contrast, the findings for the low-accuracy group revealed that the left middle occipital gyrus was activatedfor processing visual information. Conclusion: The findings suggest that the frontal lobe plays a role in allowing landscape designers to make planar tocross-sectional inferences via mental rotations and categorical spatial relations. The findings offer implications forlandscape designers in stimulating the frontal lobe and enhancing their design capabilities.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
